Published in Int J Exp Pathol on June 01, 2005
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
The amyloid-beta precursor protein: integrating structure with biological function. EMBO J (2005) 1.68
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging (2006) 1.09
Amyloid plaques in PSAPP mice bind less metal than plaques in human Alzheimer's disease. Neuroimage (2009) 1.07
Amyloid β-protein oligomers and Alzheimer's disease. Alzheimers Res Ther (2013) 1.07
Minimal Zn(2+) binding site of amyloid-β. Biophys J (2010) 0.99
Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.95
Alterations of zinc transporter proteins ZnT-1, ZnT-4 and ZnT-6 in preclinical Alzheimer's disease brain. Brain Pathol (2009) 0.94
The role of metals in modulating metalloprotease activity in the AD brain. Eur Biophys J (2008) 0.92
Zn(++) binding disrupts the Asp(23)-Lys(28) salt bridge without altering the hairpin-shaped cross-β Structure of Aβ(42) amyloid aggregates. Biophys J (2011) 0.91
Copper: from neurotransmission to neuroproteostasis. Front Aging Neurosci (2014) 0.89
Cholesterol enhances classical conditioning of the rabbit heart rate response. Behav Brain Res (2007) 0.87
Intracellular amyloid formation in muscle cells of Abeta-transgenic Caenorhabditis elegans: determinants and physiological role in copper detoxification. Mol Neurodegener (2009) 0.86
Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress Chaperones (2009) 0.86
Beta-amyloid peptides undergo regulated co-secretion with neuropeptide and catecholamine neurotransmitters. Peptides (2013) 0.86
Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. Eur Biophys J (2009) 0.86
Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there? Expert Rev Neurother (2006) 0.84
Trientine reduces BACE1 activity and mitigates amyloidosis via the AGE/RAGE/NF-κB pathway in a transgenic mouse model of Alzheimer's disease. Antioxid Redox Signal (2013) 0.83
An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation. ACS Chem Neurosci (2012) 0.82
Spin hamiltonian parameters for Cu(II)-prion peptide complexes from L-band electron paramagnetic resonance spectroscopy. J Am Chem Soc (2011) 0.82
Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J Neural Transm (Vienna) (2006) 0.82
Zinc overload enhances APP cleavage and Aβ deposition in the Alzheimer mouse brain. PLoS One (2010) 0.82
HFE gene variants, iron, and lipids: a novel connection in Alzheimer's disease. Front Pharmacol (2014) 0.81
Structure of Alzheimer's disease amyloid precursor protein copper-binding domain at atomic resolution. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.81
Metal-deficient aggregates and diminished copper found in cells expressing SOD1 mutations that cause ALS. Front Aging Neurosci (2014) 0.80
Spatial memory deficits in a mouse model of late-onset Alzheimer's disease are caused by zinc supplementation and correlate with amyloid-beta levels. Front Aging Neurosci (2014) 0.80
Latest Advances on Interventions that May Prevent, Delay or Ameliorate Dementia. Ther Adv Chronic Dis (2011) 0.79
Chronic exposure to high levels of zinc or copper has little effect on brain metal homeostasis or Abeta accumulation in transgenic APP-C100 mice. Cell Mol Neurobiol (2009) 0.79
Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet. J Alzheimers Dis (2012) 0.79
The effect of iron in MRI and transverse relaxation of amyloid-beta plaques in Alzheimer's disease. NMR Biomed (2014) 0.78
A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. Biofactors (2012) 0.77
A review of β-amyloid neuroimaging in Alzheimer's disease. Front Neurosci (2014) 0.77
Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration. Biomed Spectrosc Imaging (2013) 0.77
Combining conformational sampling and selection to identify the binding mode of zinc-bound amyloid peptides with bifunctional molecules. J Comput Aided Mol Des (2012) 0.76
Cortical iron regulation and inflammatory response in Alzheimer's disease and APPSWE/PS1ΔE9 mice: a histological perspective. Front Neurosci (2015) 0.76
Characterization of the internal dynamics and conformational space of zinc-bound amyloid β peptides by replica-exchange molecular dynamics simulations. Eur Biophys J (2013) 0.76
The role of metal regulatory proteins in brain oxidative stress: a tutorial. Oxid Med Cell Longev (2012) 0.75
The Therapeutic Potential of Rosemary (Rosmarinus officinalis) Diterpenes for Alzheimer's Disease. Evid Based Complement Alternat Med (2016) 0.75
EPR Methods for Biological Cu(II): L-Band CW and NARS. Methods Enzymol (2015) 0.75
Molecular Origins of the Compatibility Between Glycosaminoglycans and Aβ40 Amyloid Fibrils. J Mol Biol (2017) 0.75
Dansyl Based "Turn-On" Fluorescent Sensor for Cu(2+) Ion Detection and the Application to Living Cell Imaging. J Fluoresc (2017) 0.75
Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation. Biophys Rev (2017) 0.75
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science (1999) 6.86
Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science (1990) 6.03
Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem (2002) 5.63
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A (1997) 3.47
The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol (1998) 3.45
Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci (2001) 2.89
RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci (1999) 2.86
4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem (1997) 2.80
Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem (1998) 2.78
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem (1991) 2.63
The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry (1999) 2.58
Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans (2002) 2.55
The metallobiology of Alzheimer's disease. Trends Neurosci (2003) 2.47
MR detection of brain iron. AJNR Am J Neuroradiol (1993) 2.39
Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med (1999) 2.32
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
Metals and neuroscience. Curr Opin Chem Biol (2000) 2.14
Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 2.02
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev (2003) 1.97
Elevation of serum copper levels in Alzheimer's disease. Neurology (2002) 1.93
Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci U S A (1994) 1.91
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J (1998) 1.89
Manganese action in brain function. Brain Res Brain Res Rev (2003) 1.88
Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am J Pathol (2001) 1.87
Oxidative stress in Alzheimer's disease. Biochim Biophys Acta (2000) 1.84
Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem (2000) 1.82
Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1997) 1.80
Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol (2000) 1.79
A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging (2000) 1.78
MRI of brain iron. AJR Am J Roentgenol (1986) 1.76
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
Modification of glucose-6-phosphate dehydrogenase by 4-hydroxy-2-nonenal. Formation of cross-linked protein that inhibits the multicatalytic protease. J Biol Chem (1994) 1.69
Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science (1989) 1.69
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A (2002) 1.68
Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem (1998) 1.68
Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem (2001) 1.64
Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest (1999) 1.63
Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci (1998) 1.63
Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J Neurol Sci (1996) 1.62
In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem (2000) 1.60
Positron emission tomography in Alzheimer's disease. Neurology (1986) 1.52
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol (1996) 1.49
Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem (1999) 1.48
Gender differences in the amount and deposition of amyloidbeta in APPswe and PS1 double transgenic mice. Neurobiol Dis (2003) 1.48
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
Synaptically released zinc: physiological functions and pathological effects. Biometals (2002) 1.44
Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res (2000) 1.42
Metal binding modes of Alzheimer's amyloid beta-peptide in insoluble aggregates and soluble complexes. Biochemistry (2000) 1.42
Consequences of manganese replacement of copper for prion protein function and proteinase resistance. EMBO J (2000) 1.39
Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem (2003) 1.38
Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med (2001) 1.35
Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol (1992) 1.34
The beta A4 amyloid precursor protein binding to copper. FEBS Lett (1994) 1.34
A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J Biol Chem (1993) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Aberrant metal binding by prion protein in human prion disease. J Neurochem (2001) 1.33
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry (2004) 1.30
Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res (1992) 1.30
Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol (1998) 1.29
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J (2004) 1.29
Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice. Brain Res (1999) 1.27
Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem (1998) 1.27
Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem (2002) 1.26
Alzheimer Disease and Oxidative Stress. J Biomed Biotechnol (2002) 1.26
Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem (1997) 1.24
Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of abeta by zinc. J Biol Chem (2000) 1.24
Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J (1999) 1.24
Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology (1998) 1.21
Oxidative stress induces intracellular accumulation of amyloid beta-protein (Abeta) in human neuroblastoma cells. Biochemistry (2000) 1.20
Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology (2001) 1.17
Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci U S A (1993) 1.16
Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci (2004) 1.15
Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim Biophys Acta (1998) 1.14
Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem (2003) 1.14
Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun (2000) 1.14
Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem (1994) 1.13
Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model. Ann N Y Acad Sci (2000) 1.12
Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci (1999) 1.12
Genetic defects in copper metabolism. J Nutr (2003) 1.10
Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res (1998) 1.08
MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging (1997) 1.08
Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res (1996) 1.07
The role of iron and copper in the aetiology of neurodegenerative disorders: therapeutic implications. CNS Drugs (2002) 1.07
Increasing striatal iron content associated with normal aging. Mov Disord (1998) 1.07
Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods (1997) 1.05
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov (2004) 5.82
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol (2008) 3.67
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol (2010) 3.46
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med (2012) 3.31
Increased expression of the amyloid precursor beta-secretase in Alzheimer's disease. Ann Neurol (2002) 3.30
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol (2008) 3.03
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
A primer of amyloid nomenclature. Amyloid (2007) 2.70
The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr (2009) 2.54
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol (2008) 2.44
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci (2009) 2.12
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care (2013) 1.99
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol (2008) 1.98
Homo- and heterodimerization of APP family members promotes intercellular adhesion. EMBO J (2005) 1.98
C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet (2006) 1.97
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem (2005) 1.95
A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry (2002) 1.93
N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol Psychiatry (2008) 1.93
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond) (2012) 1.90
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: Abeta dimers and trimers correlate with neurotoxicity. J Neurosci (2008) 1.86
Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci (2005) 1.83
The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta (2007) 1.83
In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging (2014) 1.80
Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci (2010) 1.74
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Biol Psychiatry (2008) 1.73
18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain (2011) 1.67
PrPC-related signal transduction is influenced by copper, membrane integrity and the alpha cleavage site. Cell Res (2009) 1.64
The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. J Biol Chem (2004) 1.63
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Dopamine D2 receptor knockout mice develop features of Parkinson disease. Ann Neurol (2009) 1.62
Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia (2011) 1.62
Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology (2007) 1.61
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain (2012) 1.58
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci U S A (2013) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med (2011) 1.54
Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics (2014) 1.53
Inhibition of gamma-secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes. FASEB J (2008) 1.52
In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci (2007) 1.52
Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J (2005) 1.51
The role of exosomes in the processing of proteins associated with neurodegenerative diseases. Eur Biophys J (2007) 1.50
Plasma amyloid beta42 and amyloid beta40 levels are associated with early cognitive dysfunction after cardiac surgery. Ann Thorac Surg (2009) 1.50
Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian imaging, biomarkers and lifestyle (AIBL) study of ageing. Int Psychogeriatr (2011) 1.49
The neurophysiology and pathology of brain zinc. J Neurosci (2011) 1.46
Insulin-like signaling determines survival during stress via posttranscriptional mechanisms in C. elegans. Cell Metab (2010) 1.46
Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol (2002) 1.46
High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol (2009) 1.45
Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med (2014) 1.45
Decreased serum zinc is an effect of ageing and not Alzheimer's disease. Metallomics (2014) 1.44